Please enable JavaScript.
Coggle requires JavaScript to display documents.
Succimer, Tirzepatide, CaNa2 EDTA (calcium disodium ethylenediaminetetraac…
-
Tirzepatide
Dose in T2DM:
-
If additional glycemic control needed, increase by 2.5-mg increments after at least 4 weeks at current dose
-
-
Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
-
-
Contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2
Side effects: Nausea, Diarrhea, Decreased appetite
-
Dimercaprol
• used for acute arsenic, gold, and mercury poisoning
-
-
-
• Increases toxicity of iron, cadmium, and selenium
-
Iron Chelators
Deferoxamine
-
-
• IV, IM, or SC administration required
-
-
-
Deferasirox
-
-
-
• Renal failure, hepatic failure, and GI hemorrhage are concerns
-
-
-
Copper Chelators
Penicillamine
-
• Chelates heavy metals, but more toxic, less potent, and less selective than other options
-
-
-
-
-
-
-
Zoledronate
-
• 10,000 times more potent than etidronate
-
-
-
• Osteonecrosis of jaw, fractures of femoral shaft, anaphylaxis reported
-
-
-
-
• Adjunctive treatment of bone metastases from solid tumors and osteolytic lesions of multiple myeloma
-
-
-
Raloxifene
-
• Contraindicated in adults with history of venous thromboembolism; increased risk of deep vein thrombosis and pulmonary embolism
-
-